← Back

Wire · opportunities

Sanofi's Infilbray wins first approval for neurological symptoms of Type 3 Gaucher disease

Published

19 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

The US FDA approved Sanofi’s Infilbray (venglustat) as the first treatment for neurological symptoms of Type 3 Gaucher disease, based on Phase III trial results demonstrating superior motor and cognitive outcomes compared to imiglucerase. This is the first global approval of venglustat, with adult and pediatric indications and safety warnings included in the US label.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 18 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You now have a regulatory green light to develop therapies targeting neurological symptoms of Type 3 Gaucher disease in the US. This approval opens a new pathway for rare disease treatments crossing the blood-brain barrier to reach patients with unmet neurological needs.

◆ Coverage

7 sources · first reported 18 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvalrare-diseaseneurologySanofivenglustatclinical-trial